Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current HAM-D score of ≥ 20~* Patients with severe asthma (defined as asthma requiring three or more course of oral corticosteroids in the past year).~* No changes in asthma medications, oral corticosteroid use, or treatment for respiratory tract infections in the past week~* Needs to have taken ≥ 3 courses of oral corticosteroids, for asthma, in the past 12 months.~* Both male and female~* English- or Spanish-speaking~Exclusion Criteria:~* Current substance or alcohol abuse/dependence~* MDD with psychotic features (delusions, hallucinations, disorganized thought processes)~* Bipolar disorder~* Schizophrenia or schizoaffective disorder~* Substance-induced mood disorder and mood disorder secondary to a general medical condition~* Mental retardation or other severe cognitive impairment~* Prison or jail inmates~* Pregnant or nursing women or women of childbearing age who will not use The University of Texas Southwestern Medical Center - Institutional Review Board (UTSW IRB) approved methods of birth control or abstinence during the study~* Treatment-resistant depressed persons defined as having failed two adequate trials of antidepressants~* Current antipsychotic or antidepressant therapy or psychotherapy~* Initiation of other psychotropic medications or psychotherapy within past 2 weeks (e.g., anxiolytics, hypnotics)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Matching Escitalopram given orally daily (for a 12-week duration).
- Escitalopram (Type: ACTIVE_COMPARATOR): Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).